SUTHERLAND

999 Peachtree St., N.E.
Atlanta, GA 30309-3996
404.853.8000 Fax 404.853.8806
www.sutherland.com

ATLANTA
AUSTIN
HOUSTON
NEW YORK
WASHINGTON DC

Facsimile

CONFIDENTIAL

Date: February 3, 2010 **Pages (including cover):** 2

TO:

Recipient Name	Firm/Company	Fax	Telephone
Examiner Lynn Bristol	U.S. Patent & Trademark Office	571.273.6883	571.272.6883

FROM: WILLIAM L. WARREN **Email address:** bill.warren@sutherland.com
Telephone: 404.853.8081 **User number:** 1295 **Client number:** 20825-0004

Message:

Re: U.S. Application No. 10/799,417
Applicant: Paul A. Krieg
Title: "METHODS FOR MODULATING ANGIOGENESIS WITH APELIN COMPOSITIONS"
Our Ref. No.: 20825-0004

Dear Examiner Bristol:

Pursuant to our telephone interview on February 2, 2010 to discuss the enablement issue; enclosed please find a proposed set of claims to overcome the objections.

Regards,

William L. Warren
Reg. No. 36,714

U.S. Utility Patent Application Serial No. 10/799,417 entitled,
"METHODS FOR MODULATING ANGIOGENESIS WITH APELIN COMPOSITIONS"

PROPOSED AMENDMENTS FOR DISCUSSION – DO NOT ENTER

1. (Currently Amended) A method of inhibiting angiogenesis in a biological sample, comprising
   a. providing a biological sample; and
   b. combining the biological sample in vivo with an angiogenesis-inhibiting amount of a composition comprising ~~an inhibitor of apelin activity~~ an anti-apelin antibody or fragment thereof that binds the apelin polypeptide of SEQ ID NO:4 and inhibits angiogenesis, wherein the angiogenesis is characterized by in vivo generation of a new blood vessel from an existing blood vessel.

2. (Original) The method of Claim 1, wherein the composition decreases vascular permeability in the biological sample.

3. (Currently Amended) The method of Claim 1, wherein the composition interferes with the interaction of ~~an~~ the apelin polypeptide ~~or apelin peptide~~ with a receptor polypeptide.

4. (Currently Amended) The method of Claim 1, wherein the composition interferes with the interaction of ~~an~~ the apelin polypeptide ~~or apelin peptide~~ with APJ.

5-20 (Canceled)

21. (Original) The method of Claim 1, wherein the composition comprises a pharmaceutically acceptable carrier.

22. (Previously Presented) The method of Claim 1, wherein the biological sample is a mammalian biological sample.

23. (Original) The method of Claim 1, wherein the biological sample is a human biological sample.

24. (Original) The method of Claim 23, wherein the biological sample is in a patient.

25-59. (Canceled)